[FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection].
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007880:Legislation, Drug; D010446:Peptide Fragments / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide
La FDA autoriza el primero de una nueva clase de tratamientos antirretrovíricos para adultos y niños en etapa avanzada de infección por el VIH.